Abstract
BackgroundMany immuno-oncology drugs fail in clinical trials, which is partly due to the lack of in vitro and in vivo models that sufficiently recapitulate the tumor microenvironment (TME). To bridge...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
